{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/food-allergy/prescribing-information/oral-antihistamines/","result":{"pageContext":{"chapter":{"id":"8b3f841c-b1b6-5db8-afec-67e6512866cc","slug":"oral-antihistamines","fullItemName":"Oral antihistamines","depth":2,"htmlHeader":"<!-- begin field 98e8bdc4-2688-4328-bb17-a8e200ba443a --><h2>Oral antihistamines</h2><!-- end field 98e8bdc4-2688-4328-bb17-a8e200ba443a -->","summary":"","htmlStringContent":"<!-- begin item 9bb57ecc-1456-4b25-bc45-a8e200ba443a --><!-- end item 9bb57ecc-1456-4b25-bc45-a8e200ba443a -->","topic":{"id":"1201eac3-a4d0-5c6b-b1ea-1c0bc61f769f","topicId":"737c0cbe-f311-4cd4-b0c7-a8e200ba3b87","topicName":"Food allergy","slug":"food-allergy","lastRevised":"Last revised in October 2018","chapters":[{"id":"8d20a28e-fd5e-5f50-8ef7-77722ddaa8bb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d336b385-69d9-50a3-a039-57439624276e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4fd46164-3019-562b-99bd-28f24976fe69","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c89b0fe4-ece1-5733-851c-2624cd40c59f","slug":"changes","fullItemName":"Changes"},{"id":"8a4996af-5513-5012-8c3c-0e5429277802","slug":"update","fullItemName":"Update"}]},{"id":"22e003d2-6f14-5844-95b4-ee26fa9d84c9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"39729080-16cf-5454-9dc1-86881f000186","slug":"goals","fullItemName":"Goals"},{"id":"dcecd8a6-d28b-5e83-b9b1-bb1de904c627","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df239dfe-bf5d-5e4c-8705-b1b1475ec181","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c9685590-9199-52c5-9bd4-bbcc22058c75","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6dafa67e-272a-5ce1-930d-eda7a3e0da1e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7d9b4122-7a51-57e7-a80a-047e1af23ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"62d8b324-7ef3-5f7e-8d1b-15ccec8f04c3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"fc75e8bc-ec94-5841-816f-487c4e0c47d8","slug":"definition","fullItemName":"Definition"},{"id":"961d240b-04de-57a4-9a56-1aca58afafda","slug":"causes","fullItemName":"Causes"},{"id":"742d8232-287c-561d-b3b5-b8b00c53d04f","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"372282ee-16ad-5e06-b91c-b6bb9144fae0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1a53ba52-7050-56c6-833b-9d86de2c7e1b","slug":"complications","fullItemName":"Complications"},{"id":"3e854238-6333-52a7-bb04-d71486dea9b2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25ec57ae-e77e-5493-9843-763b41bfbb1f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9d8e9a66-c799-53b6-bd1d-633c815d4b42","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4917fa86-b95c-5b7b-9c49-f7ea35400bc4","slug":"assessment","fullItemName":"Assessment"},{"id":"7b51cdb3-267b-5dc3-9856-a774af6ba716","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d9e076e7-32b6-5ff8-9b33-20a9c52473fb","fullItemName":"Management","slug":"management","subChapters":[{"id":"2612e752-13d6-5341-aed1-ebdae235a3f6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9656928e-f850-51fd-bce8-72cb97b516d7","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b3f841c-b1b6-5db8-afec-67e6512866cc","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"}]},{"id":"accd346c-0265-58bd-90ab-89539cd9f77a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e0c6e97b-6f2a-5269-8c49-b98dfbfce99c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9f857e40-5848-591c-a670-c5ccda3189aa","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a6119a24-8ece-5095-902f-6a2241a1c3a8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c0ba02a6-e8de-5377-a0c3-602d9104ec9f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"40157716-a438-5b1e-9898-5cf390591310","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3d16c985-7039-586e-8c85-7325dab8c98c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cac3aec4-6f12-5ef9-8188-169b0fa8aa09","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9656928e-f850-51fd-bce8-72cb97b516d7","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"eec122ce-3be2-54b2-819c-2f9a5f725a04","slug":"dose-regimens","fullItemName":"Dose regimens","depth":3,"htmlHeader":"<!-- begin field 51c1b2db-1d2b-4025-a260-a8e200ba443a --><h3>Dose regimens</h3><!-- end field 51c1b2db-1d2b-4025-a260-a8e200ba443a -->","summary":"","htmlStringContent":"<!-- begin item 44c5f5a5-2eaa-4500-afa4-a8e200ba443a --><!-- begin field d4d6e5ac-1c3d-420c-a66d-a8e200ba443a --><ul><li><strong>Chlorphenamine maleate syrup is not licensed for use in children under 1 year of age.</strong> A suggested dose regimen is:<ul><li>Children aged 1–23 months — 1 mg twice daily.</li></ul></li><li><strong>Cetirizine hydrochloride is not licensed for use in children under 2 years of age.</strong> A suggested dose regimen is:<ul><li>Children aged 1 year — 250 micrograms/kg twice daily (off-label).</li><li>Children aged 2–5 years — 2.5 mg twice daily.</li><li>Children aged 6–11 years — 5 mg twice daily.</li><li>Children aged 12 and over, and adults — 10 mg once daily.</li></ul></li><li><strong>Loratadine is not licensed for use in children under 2 years of age.</strong> A suggested dose regimen is:<ul><li>Children aged 2–11 years and body weight up to 31 kg — 5 mg once a day.</li><li>Children aged 2–11 years and body weight 31 kg and over — 10 mg once a day.</li><li>Children aged 12 years and over, and adults — 10 mg once a day.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF 76, 2018</a>]</p><!-- end field d4d6e5ac-1c3d-420c-a66d-a8e200ba443a --><!-- end item 44c5f5a5-2eaa-4500-afa4-a8e200ba443a -->","subChapters":[]},{"id":"99772900-a8cd-58ae-91a3-5faca774e271","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 879d04b2-e6d0-4bf5-95c5-a97a0116c05a --><h3>Contraindications and cautions</h3><!-- end field 879d04b2-e6d0-4bf5-95c5-a97a0116c05a -->","summary":"","htmlStringContent":"<!-- begin item 81f1c8ae-f1eb-4b95-8a41-a97a0116c00f --><!-- begin field 019b7c15-aa6b-465a-8b8b-a97a0116c05a --><ul><li><strong>Do not prescribe cetirizine to people with:</strong><ul><li>Severe renal impairment — estimated glomerular filtration rate (eGFR) less than 10 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li><strong>Prescribe chlorphenamine with caution to people with:</strong><ul><li>Epilepsy.</li><li>Prostatic hypertrophy.</li><li>Pyloroduodenal obstruction.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Urinary retention.</li></ul></li><li><strong>Prescribe cetirizine with caution to people with:</strong><ul><li>Epilepsy.</li><li>Renal impairment<ul><li>If the eGFR is 30–50 mL/min/1.73 m<sup>2</sup>, use half the normal dose.</li><li>If the eGFR is 10–30 mL/min/1.73 m<sup>2</sup>, use half the normal dose and reduce the dose frequency to alternate days.</li></ul></li></ul></li><li><strong>Prescribe loratadine with caution to people with:</strong> <ul><li>Severe hepatic impairment — reduce the dose frequency to alternate days.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF 76, 2018</a>]</p><!-- end field 019b7c15-aa6b-465a-8b8b-a97a0116c05a --><!-- end item 81f1c8ae-f1eb-4b95-8a41-a97a0116c00f -->","subChapters":[]},{"id":"f08b14df-8cd4-5127-9ec1-e4ca537684d7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ebaf5088-5324-4cbc-8156-a97a0116df05 --><h3>Adverse effects</h3><!-- end field ebaf5088-5324-4cbc-8156-a97a0116df05 -->","summary":"","htmlStringContent":"<!-- begin item 87712fa6-2002-4d40-bf90-a97a0116dec9 --><!-- begin field c34f18bd-5039-4ef0-99cb-a97a0116df05 --><ul><li><strong>Possible adverse effects of chlorphenamine, cetirizine, and loratadine include:</strong><ul><li>Blurred vision, dry mouth, headache, diarrhoea, psychomotor impairment, urinary retention.</li><li>Drowsiness (frequency not known) — cetirizine and loratadine cause less sedation and psychomotor impairment than first-generation antihistamines such as chlorphenamine, because they penetrate the blood brain barrier to a lesser extent.<ul><li>Advise people taking non-sedating antihistamines that some people may experience sedation, which may affect their ability to drive, and that the sedative effects are enhanced when combined with alcohol.</li></ul></li><li>Angio-oedema, arrhythmias, blood disorders, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, liver dysfunction, photosensitivity reactions, rashes, sleep disturbances, tremor, angle-closure glaucoma (in adults).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF 76, 2018</a>]</p><!-- end field c34f18bd-5039-4ef0-99cb-a97a0116df05 --><!-- end item 87712fa6-2002-4d40-bf90-a97a0116dec9 -->","subChapters":[]},{"id":"8b68a865-c988-5f4e-af01-1026d5cd1341","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5a310a70-f25c-4626-bec0-a97a01170238 --><h3>Drug interactions</h3><!-- end field 5a310a70-f25c-4626-bec0-a97a01170238 -->","summary":"","htmlStringContent":"<!-- begin item a9b5203a-ab87-40c0-be1b-a97a01170201 --><!-- begin field 22713358-93c7-4338-8c43-a97a01170238 --><ul><li><p><strong>Possible drug interactions with cetirizine and loratadine include:</strong></p><ul><li><strong>Betahistine</strong> — cetirizine and loratadine are predicted to decrease the effects of betahistine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF 76, 2018</a>] </p><!-- end field 22713358-93c7-4338-8c43-a97a01170238 --><!-- end item a9b5203a-ab87-40c0-be1b-a97a01170201 -->","subChapters":[]},{"id":"b0f92109-ff9f-5b1e-890b-17b3e6c246cb","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 13ec3484-d82f-42a7-b8f4-a97a01172e62 --><h3>Pregnancy and breastfeeding</h3><!-- end field 13ec3484-d82f-42a7-b8f4-a97a01172e62 -->","summary":"","htmlStringContent":"<!-- begin item 174a5f06-5ccc-4b18-9612-a97a01172e26 --><!-- begin field f3ddd930-e58d-46df-8744-a97a01172e62 --><h4>Pregnancy</h4><ul><li>There is limited data on the use of cetirizine and loratadine in pregnancy, however, there is no evidence of harm. </li><li>The manufacturer advises these drugs should be used with caution in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>Cetirizine and loratadine are excreted in breast milk, and large doses or more prolonged use may inhibit lactation or cause drowsiness and other adverse effects in the infant.<ul><li>Small, occasional doses are not expected to cause adverse effects. </li></ul></li><li>The manufacturer advises caution if used in women who are breastfeeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">LactMed, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/food-allergy/references/\">BNF 76, 2018</a>]</p><!-- end field f3ddd930-e58d-46df-8744-a97a01172e62 --><!-- end item 174a5f06-5ccc-4b18-9612-a97a01172e26 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}